URGN - ユ―ロジェン・ファ―マ (UroGen Pharma Ltd.)

URGNのニュース

   UroGen Pharma to Present at Upcoming Investor Conferences  2022/05/18 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences: H.C. Wainwright & Co. Global Investment Conference Wednesday, May 25 at 11:00 a.m. ET Jefferies Healthcare Conference Thursday, June 9 at 1:00 p.m. ET Webcasts of both the H.C. Wainwright & Co. and Jefferies presenta
   UroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial Cancer  2022/05/16 18:50:00 Wallstreet:Online
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to creating novel solutions that treat urothelial and specialty cancers, today highlights new data on real-world experience utilizing the antegrade approach via nephrostomy tube for administration of JELMYTO (mitomycin) for pyelocalyceal solution. This data adds to a growing body of evidence on the safety and efficacy profile of the
   Oppenheimer Equities Analysts Raise Earnings Estimates for UroGen Pharma Ltd. (NASDAQ:URGN)  2022/05/16 05:31:13 ForexTV
Stock analysts at Oppenheimer increased their Q2 2022 EPS estimates for UroGen Pharma in a research report issued on Wednesday, May 11th. Oppenheimer analyst L. Gershell now expects that the company … Read Full Story at source (may require registration) The post Oppenheimer Equities Analysts Raise Earnings Estimates for UroGen Pharma Ltd. (NASDAQ:URGN) appeared first on ForexTV .
   UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call Transcript  2022/05/10 20:35:26 Seeking Alpha
UroGen Pharma Ltd. (NASDAQ:NASDAQ:URGN) Q1 2022 Earnings Conference Call May 10, 2022, 10:00 AM ET Company Participants Vincent Perrone - Senior Director of IR Liz Barrett - President and…
   UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M (NASDAQ:URGN)  2022/05/10 13:10:07 Seeking Alpha
UroGen Pharma press release (NASDAQ:URGN): Q1 GAAP EPS of -$1.25 beats by $0.09.Revenue of $13.56M (+81.0% Y/Y) misses by $1.62M.
   UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022  2022/03/04 20:00:00 Investors Urogen
Conference Call and Webcast Scheduled for Thursday, March 10, 2022 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
   UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference  2022/02/28 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time. A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of th
   UroGen begins phase 3 trial of UGN-102 to treat bladder cancer  2022/02/03 16:24:48 Seeking Alpha
UroGen Pharma <> began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive
   UroGen Pharma Ltd. (NASDAQ:URGN) Expected to Post Quarterly Sales of $17.20 Million  2021/12/22 21:08:42 Dakota Financial News
Wall Street analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN) will announce sales of $17.20 million for the current quarter, Zacks reports. Two analysts have issued estimates for UroGen Pharmas earnings. The lowest sales estimate is $16.50 million and the highest is $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last []
   UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Bank of America Corp DE  2021/12/12 09:28:42 Dakota Financial News
Bank of America Corp DE grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 169.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,635 shares of the companys stock after buying an additional 56,313 shares during the period. Bank of America []
   UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022  2022/03/04 20:00:00 Investors Urogen
Conference Call and Webcast Scheduled for Thursday, March 10, 2022 , at 10:00 AM ET PRINCETON, N.J. --(BUSINESS WIRE)--Mar. 4, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,
   UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference  2022/02/28 13:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions to treat urothelial and specialty cancers, today announced that it will participate in a panel discussion at the upcoming virtual Cowen 42nd Annual Healthcare Conference on March 8, 2022 at 10:30am Eastern Time. A live webcast of the panel will be available on the Investors & Media section of UroGen’s website at www.urogen.com. A replay of th
   UroGen begins phase 3 trial of UGN-102 to treat bladder cancer  2022/02/03 16:24:48 Seeking Alpha
UroGen Pharma <> began a phase 3 trial, dubbed ENVISION, of UGN-102 (mitomycin) for intravesical solution, in patients with low-grade, intermediate-risk non-muscle invasive
   UroGen Pharma Ltd. (NASDAQ:URGN) Expected to Post Quarterly Sales of $17.20 Million  2021/12/22 21:08:42 Dakota Financial News
Wall Street analysts forecast that UroGen Pharma Ltd. (NASDAQ:URGN) will announce sales of $17.20 million for the current quarter, Zacks reports. Two analysts have issued estimates for UroGen Pharmas earnings. The lowest sales estimate is $16.50 million and the highest is $17.90 million. UroGen Pharma reported sales of $7.97 million during the same quarter last []
   UroGen Pharma Ltd. (NASDAQ:URGN) Shares Purchased by Bank of America Corp DE  2021/12/12 09:28:42 Dakota Financial News
Bank of America Corp DE grew its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 169.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 89,635 shares of the companys stock after buying an additional 56,313 shares during the period. Bank of America []

calendar